Effect of competition bias in safety signal generation: Analysis of a research database of spontaneous reports in France

Drug Safety

Volumn 35, Issue 10, 2012, Pages 855-864

  Pariente, Antoine ^a,b,c   Avillach, Paul ^a,b,c   Salvo, Francesco ^a,d   Thiessard, Frantz ^a,b,c   Miremont Salam, Ghada ^b,c   Fourrier Reglat, Annie ^a,b,c   Haramburu, Franoise ^b,c   Bgaud, Bernard ^a,b,c   Moore, Nicholas ^a,b,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Adverse reaction monitoring; Gastric haemorrhage; Ischaemic heart disorders; Liver disorders; Liver dysfunction; Migraine; Muscle pain; Oesophageal haemorrhage; Stroke

Indexed keywords

ALBINTERFERON ALPHA2B; AMINEPTINE; ANALGESIC AGENT; ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIPYRETIC AGENT; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; BLEOMYCIN; CALCIUM CHANNEL BLOCKING AGENT; ETHINYLESTRADIOL; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; KETOCONAZOLE; LEFLUNOMIDE; MONTELUKAST; NEVIRAPINE; NITRIC ACID DERIVATIVE; ONDANSETRON; OPIATE; PREDNISONE; PROGUANIL; RITONAVIR; SEROTONIN ANTAGONIST; TACRINE; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMPETITION; CORONARY ARTERY DISEASE; DATA BASE; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG SAFETY; ESOPHAGUS HEMORRHAGE; FRANCE; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; KNOWLEDGE; LIVER FUNCTION; MIGRAINE; MYALGIA; PRIORITY JOURNAL; SIDE EFFECT; STOMACH HEMORRHAGE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIAS (EPIDEMIOLOGY); DATA MINING; DATABASES, FACTUAL; FRANCE; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84866138505     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11631780-000000000-00000     Document Type: Article

References (48)

1. Begaud B, Chaslerie A, Haramburu F. Organization and results of drug vigilance in France. Rev Epidemiol Sante Publique 1994; 42 (5): 416-23
2. Rawlins MD. Spontaneous reporting of adverse drug reactions. II: Uses. Br J Clin Pharmacol 1988 Jul; 26 (1): 7-11
3. Rawlins MD. Spontaneous reporting of adverse drug reactions. I: the data. Br J Clin Pharmacol 1988 Jul; 26 (1): 1-5
4. van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002 Jan-Feb; 11 (1): 3-10
5. Pariente A, Daveluy A, Laribiere-Benard A, et al. Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA. Drug Saf 2009; 32 (5): 441-7
6. Pariente A, Gregoire F, Fourrier-Reglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007; 30 (10): 891-8
7. van Puijenbroek EP, van Grootheest K, Diemont WL, et al. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol 2001 Nov; 52 (5): 579-86
8. Moore N, Hall G, Sturkenboom M, et al. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003 Jun; 12 (4): 271-81
9. Pariente A, Didailler M, Avillach P, et al. A potential competition bias in the detection of safety signals from spontaneous reporting databases. Pharmacoepidemiol Drug Saf 2010 Nov; 19 (11): 1166-71
10. Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf 2003 Oct-Nov; 12 (7): 559-74
11. Wang HW, Hochberg AM, Pearson RK, et al. An experimental investigation of masking in the US FDA adverse event reporting system database. Drug Saf 2010 Dec 1; 33 (12): 1117-33
12. Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985; 2 (8463): 1056-8
13. Thiessard F, Roux E, Miremont-Salame G, et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001). Drug Saf 2005; 28 (8): 731-40
14. Pearson RK, Hauben M, Goldsmith DI, et al. Influence of the MedDRA hierarchy on pharmacovigilance data mining results. Int J Med Inform 2009 Dec; 78(12): e97-e103
15. Dukes M, Aronson J. Meyler's side effects of drugs. 14th ed. Amsterdam: Elsevier, 2000
16. Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French phar-macovigilance system database. Br J Clin Pharmacol 1997 Nov; 44 (5): 513-8
17. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994 Feb; 10 (2): 93-102
18. Bickerman HA, Beck GJ, Barach AL. The use of prednisone (Meticorten) in respiratory disease. II. Pulmonary emphysema and pulmonary fibrosis. J Chronic Dis 1955 Sep; 2 (3): 247-59
19. Nielsen GL, Sorensen HT, Mellemkjoer L, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med 2001 Nov; 111 (7): 541-5
20. Radmanesh M. Anal fissure, rectal bleeding and proctitis as complications of systemic isotretinoin therapy: report of two cases [letter]. J Eur Acad Dermatol Venereol 2006 Nov; 20 (10): 1394
21. Amalfitano G, Pernod G, Mallaret M, et al. Risk of intracerebral hematoma and profibrinolytic activity of iso-tretinoin. Therapie 1995 Sep-Oct; 50 (5): 479-81
22. Dootson GM, Keidan J, Anderson JA. Exacerbation of bleeding tendency in a patient with haemophilia A during treatment with isotretinoin. Br J Dermatol 1992 Aug; 127 (2): 186-7
23. Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996 Jun; 30 (6): 416-44
24. Bortolotto LA, Silva HB, Pileggi F. Cardiac and neurologic complications in malignant hypertension due to oral contraceptive use. Blood Press 1994 Sep; 3 (5): 319-21
25. Johnston SC, Colford Jr JM, Gress DR. Oral contraceptives and the risk of subarachnoid hemorrhage: a meta-analysis. Neurology 1998 Aug; 51 (2): 411-8
26. Thorogood M, Mann J, Murphy M, et al. Fatal stroke and use of oral contraceptives: findings from a case-control study. Am J Epidemiol 1992 Jul 1; 136 (1): 35-45
27. Bailly F, Mattei A, SiAhmed SN, et al. Uncommon sideeffects of interferon. J Viral Hepat 1997; 4 Suppl. 1: 89-94
28. Niederwieser G, Bonelli RM, Kammerhuber F, et al. Intracerebral haemorrhage under interferon-beta therapy. Eur J Neurol 2001 Jul; 8 (4): 363-4
29. Nishiofuku M, Tsujimoto T, Matsumura Y, et al. Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Intern Med 2006; 45 (7): 483-4
30. Ruigrok YM, Dekkers PJ, Bromberg JE, et al. Corticosteroid use and risk of aneurysmal subarachnoid haemorrhage. J Neurol 2006 Apr; 253 (4): 496-9
31. Ballard HS, Bottino G, Bottino J. Ondansetron and chest pain [letter]. Lancet 1992 Oct 31; 340 (8827): 1107
32. Bosek V, Hu P, Robinson LA. Acute myocardial ischemia after administration of ondansetron hydrochloride. An-esthesiology 2000 Mar; 92 (3): 885-7
33. Markham A, Faulds D. Montelukast. Drugs 1998 Aug; 56 (2): 251-6; discussion 7
34. Price D. Tolerability of montelukast. Drugs 2000; 59 Suppl. 1: 35-42; discussion 3-5
35. Bustos DG, Canfield CJ, Canete-Miguel E, et al. Atovaquone-proguanil compared with chloroquine and chloro-quine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis 1999 Jun; 179 (6): 1587-90
36. Sukwa TY, Mulenga M, Chisdaka N, et al. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999 Apr; 60 (4): 521-5
37. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000 Jun; 39 (6): 655-65
38. Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999 Dec; 58 (6): 1137-64
39. Montgomery SA, Prost JF, Solles A, et al. Efficacy and tolerability of milnacipran: an overview. Int Clin Psycho-pharmacol 1996 Sep; 11 Suppl. 4: 47-51
40. Regina W, Vandel P, Vandel S, et al. Clinical tolerance of a new antidepressant-milnacipran. Encephale 1999 May-Jun; 25 (3): 252-8
41. Geisser ME, Palmer RH, Gendreau RM, et al. A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia. Pain Pract 2011 Mar; 11 (2): 120-31
42. Cook JE, Kolka MA, Wenger CB. Chronic pyridostigmine bromide administration: side effects among soldiers working in a desert environment. Mil Med 1992 May; 157 (5): 250-4
43. Chattha G, Arieff AI, Cummings C, et al. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med 1993 Jan 1; 118 (1): 37-9
44. Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000 Dec; 27 (12): 2927-31
45. Richards AJ. Hydroxychloroquine myopathy. J Rheumatol 1998 Aug; 25 (8): 1642-3
46. Desilets DJ, Shorr AF, Moran KA, et al. Cholestatic jaundice associated with the use of metformin. Am J Gastro-enterol 2001 Jul; 96 (7): 2257-8
47. Babich MM, Pike I, Shiffman ML. Metformin-induced acute hepatitis. Am J Med 1998 May; 104 (5): 490-2
48. Cadden IS, Partovi N, Yoshida EM. Review article: possible beneficial effects of coffee on liver disease and function. Aliment Pharmacol Ther 2007 Jul 1; 26 (1): 1-8